NASDAQ: RLYBRallybio Corp Stock
$8.49+0.49 (+6.13%)
Updated Jun 5, 2023
RLYB Price
$8.49
Fair Value Price
N/A
Market Cap
$320.48M
52 Week Low
$4.15
52 Week High
$15.89
P/E
-4.16x
P/B
2.06x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$69.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$62M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RLYB Overview
Rallybio Corporation is a clinical-stage biotechnology company offering programs for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company is also focused on developing therapies that address diseases of complement dysregulation, including Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, and ophthalmic disorders. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, CT.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RLYB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RLYB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RLYB is good value based on its book value relative to its share price (2.06x), compared to the US Biotechnology industry average (5.21x)
P/B vs Industry Valuation
RLYB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RLYB due diligence checks available for Premium users.
Be the first to know about important RLYB news, forecast changes, insider trades & much more!
RLYB News
Valuation
RLYB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.16x
Industry
11.59x
Market
53.21x
RLYB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.06x
Industry
5.21x
RLYB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RLYB's financial health
Profit margin
Revenue
$0.0
Net Income
-$17.3M
Profit Margin
0%
RLYB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$162.3M
Liabilities
$7.1M
Debt to equity
0.05
RLYB's short-term assets ($161.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLYB's short-term assets ($161.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLYB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.8M
Investing
$1.5M
Financing
-$139.0k
RLYB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RLYB vs Biotech Stocks
Rallybio Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.